GlassScriptPhysician profile
Upali S Walgama
NPI 1265577175
$2,160.27
in general payments reported to CMS, 2019-2025
19 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $71.31 · 2022: $74.13 · 2023: $611 · 2024: $521 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.07 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $366.68 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $215.76 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $200.14 | 2024-2025 | |
| Pfizer INC. | $182.65 | 2019-2024 | |
| Glaxosmithkline, LLC. | $152.43 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $123.31 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $108.22 | 2022-2025 | Seglentis, Livalo, Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.01 | 2019-2025 | Jardiance |
| Shield Therapeutics INC | $67.41 | 2024 | |
| Abbott Laboratories | $57.39 | 2025 | Freestyle Libre 3 |
| Medtronic Vascular, INC. | $53.67 | 2020 | |
| Esperion Therapeutics, INC. | $30.27 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.96 | 2023-2025 | Xifaxan |
| Antares Pharma, INC. | $24.00 | 2023 | Tlando, Xyosted, Nocdurna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $20.11 | 2024 | Inspire |
| Acella Pharmaceuticals, LLC | $19.97 | 2025 | NP Thyroid 60 |
| Amgen INC. | $16.28 | 2023 | Prolia, Evenity |
| Phathom Pharmaceuticals, INC. | $7.94 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upali Walgama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.